CU20220068A7 - Composición inmune que contiene ácido polirriboinosínico-polirribocitidílico, un antibiótico o un compuesto poliamino, y un ion positivo - Google Patents

Composición inmune que contiene ácido polirriboinosínico-polirribocitidílico, un antibiótico o un compuesto poliamino, y un ion positivo

Info

Publication number
CU20220068A7
CU20220068A7 CU2022000068A CU20220068A CU20220068A7 CU 20220068 A7 CU20220068 A7 CU 20220068A7 CU 2022000068 A CU2022000068 A CU 2022000068A CU 20220068 A CU20220068 A CU 20220068A CU 20220068 A7 CU20220068 A7 CU 20220068A7
Authority
CU
Cuba
Prior art keywords
polyriboinosinic
antibiotic
composition containing
positive ion
immune composition
Prior art date
Application number
CU2022000068A
Other languages
English (en)
Inventor
Yuan Liu
Nan Zhang
Yi Zhang
Original Assignee
Beijing Yisheng Biotechnology Co Ltd
Liaoning Yisheng Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Yisheng Biotechnology Co Ltd, Liaoning Yisheng Biopharma Co Ltd filed Critical Beijing Yisheng Biotechnology Co Ltd
Publication of CU20220068A7 publication Critical patent/CU20220068A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>La presente invención se refiere a una composición inmune que contiene ácido polirriboinosínico-polirribocitidílico (PIC), un antibiótico o un compuesto poliamino, y un ion positivo. Asimismo, la presente invención se refiere a dicha composición inmune que contiene además un antígeno derivado de coronavirus, en el que el coronavirus es SARS-CoV-2 o una variante del mismo.</p> <p> </p> <p> </p>
CU2022000068A 2020-05-29 2021-05-26 Composición inmune que contiene ácido polirriboinosínico-polirribocitidílico, un antibiótico o un compuesto poliamino, y un ion positivo CU20220068A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010475388 2020-05-29
PCT/CN2021/096048 WO2021238982A1 (zh) 2020-05-29 2021-05-26 包含聚核苷酸的药物组合物及其用于预防或治疗covid-19的用途

Publications (1)

Publication Number Publication Date
CU20220068A7 true CU20220068A7 (es) 2023-06-13

Family

ID=78745583

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2022000068A CU20220068A7 (es) 2020-05-29 2021-05-26 Composición inmune que contiene ácido polirriboinosínico-polirribocitidílico, un antibiótico o un compuesto poliamino, y un ion positivo

Country Status (14)

Country Link
US (1) US20230081039A1 (es)
EP (1) EP4159233A4 (es)
JP (1) JP2023540643A (es)
KR (1) KR20230013133A (es)
CN (1) CN114340662A (es)
AU (1) AU2021278137A1 (es)
BR (1) BR112022024186A2 (es)
CA (1) CA3178162A1 (es)
CU (1) CU20220068A7 (es)
IL (1) IL298611A (es)
MX (1) MX2022014676A (es)
TW (1) TW202207978A (es)
WO (1) WO2021238982A1 (es)
ZA (1) ZA202212363B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019133804A1 (en) 2017-12-28 2019-07-04 Consegna Pharma Inc. Long acting opioid antagonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1056315C (zh) * 1993-05-31 2000-09-13 林海祥 聚肌胞复合物免疫佐剂及含有该佐剂的疫苗
CN103405762A (zh) 2005-06-08 2013-11-27 依生生物制药(新加坡)私人有限公司 以聚肌苷酸-聚胞苷酸为主的佐剂
KR101203401B1 (ko) * 2005-06-08 2012-11-22 이쉥 바이오파마(싱가포르)피티이 리미티드 폴리이노신산-폴리시티딜산-기초 보조제
US20070166800A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
CN105396130A (zh) * 2015-11-10 2016-03-16 林海祥 皮氨钙佐剂及含有皮氨钙佐剂的疫苗
CN106075431A (zh) * 2016-03-23 2016-11-09 林海祥 皮氨钙联合佐剂及含有皮氨钙联合佐剂的疫苗
CN107198777A (zh) * 2016-04-01 2017-09-26 依生生物制药(新加坡)私人有限公司 用于治疗癌症的含有聚核苷酸的药物组合物
WO2018115527A2 (en) * 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
US11135286B2 (en) * 2017-08-10 2021-10-05 Yisheng Biopharma (Singapore) Pte Ltd Composition for treating and/or preventing Hepatitis B virus infection and the use thereof
CN108992667A (zh) * 2018-08-09 2018-12-14 安徽智飞龙科马生物制药有限公司 一种带状疱疹疫苗及其制备方法、应用
CN110951756B (zh) * 2020-02-23 2020-08-04 广州恩宝生物医药科技有限公司 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用
CN110974950B (zh) * 2020-03-05 2020-08-07 广州恩宝生物医药科技有限公司 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗
CN111560074B (zh) 2020-03-20 2021-07-09 中山大学 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗
CN111607605B (zh) 2020-05-27 2023-10-24 重庆医科大学 一种多价表位和亚单位疫苗的构建方法

Also Published As

Publication number Publication date
MX2022014676A (es) 2022-12-16
CN114340662A (zh) 2022-04-12
CA3178162A1 (en) 2021-12-02
TW202207978A (zh) 2022-03-01
AU2021278137A1 (en) 2023-01-05
JP2023540643A (ja) 2023-09-25
US20230081039A1 (en) 2023-03-16
WO2021238982A1 (zh) 2021-12-02
BR112022024186A2 (pt) 2022-12-20
EP4159233A1 (en) 2023-04-05
IL298611A (en) 2023-01-01
KR20230013133A (ko) 2023-01-26
ZA202212363B (en) 2023-03-29
EP4159233A4 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
CU24743B1 (es) Composiciones inmunogénicas contra el coronavirus
CO2018003134A2 (es) Composiciones para el cuidado bucal que comprenden un aminoácido básico, una combinación de fuentes de iones de zinc y un sistema quelante
BR112022005896A2 (pt) Inibidores da mek para o tratamento de infecções causadas por hantavírus
ECSP19062769A (es) Formulación de anticuerpo monoclonal anti-vrs
AR108240A1 (es) Formulaciones que contienen anticuerpos
BR112018071678A2 (pt) compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv
AR121361A1 (es) Vacuna
MX2019010282A (es) Formulacion de anticuerpos monoclonales.
MX344973B (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina.
CL2023003124A1 (es) Anticuerpos anti-tslp modificados
CO2020013552A2 (es) Formulación de anticuerpos
UY29915A1 (es) Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
BR112015024938A2 (pt) formulação, uso de formulações, e, processo para preparação de formulações
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
MX2021014680A (es) Derivado de benzotriazol.
CO2021015337A2 (es) Métodos y composiciones que comprenden variantes de la proteína a de estafilococos (spa)
BR112022022467A2 (pt) Composições para tratamento bucal que compreendem ácido dicarboxílico
CL2020002128A1 (es) Composición herbicida que comprende por lo menos un compuesto activo fenólico
CU20200009A7 (es) Composiciones para tratar y/o prevenir la infección por el virus de la hepatitis b
MX420767B (es) Proteina de union al factor h modificada
BR112023022917A2 (pt) Moduladores de trex1
WO2018170236A9 (en) CDPK1 INHIBITORS, COMPOSITIONS AND RELATED METHODS
MX2022001167A (es) Metodo para el tratamiento de una composicion que comprende vainillina natural.